

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

**VOLUNTARY ANNOUNCEMENT
CHINA NMPA APPROVES CLINICAL TRIAL OF
PD-L1/TGF- β DUAL-TARGETING ANTIBODY (GT90008) FOR THE
TREATMENT OF ADVANCED SOLID TUMOURS**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) is pleased to announce that the clinical trial of PD-L1/TGF- β dual-targeting antibody (GT90008) for the treatment of advanced solid tumours was approved by the National Medical Products Administration (NMPA) of China on 21 October 2021.

GT90008 is the Company’s second novel antibody drug that has entered clinical stage. It is a PD-L1/TGF- β dual-targeting antibody which has a high activity in inhibiting both PD-L1 and TGF- β R2. Genetic engineering modification could reduce degradation or fragmentation of GT90008 in Chinese hamster ovary (CHO) cell expression proteins, which makes it easier to be commercially produced. In addition, the Company will also actively pursue the clinical strategies of GT90008 combined with ALK-1 antibody (GT90001) in the treatment of advanced tumours.

Previously, the Group entered into an exclusive license agreement in respect of GT90008 with US-based company Gensun Biopharma Inc. For further details, please refer to the announcement of the Company dated 20 August 2020.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that GT90008 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 21 October 2021

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*